Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
CD30 by Wuhan Bio-Raid Biotechnology for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma): Likelihood of Approval
CD30 is under clinical development by Wuhan Bio-Raid Biotechnology and currently in Phase I for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)....
CD30 by Wuhan Bio-Raid Biotechnology for Peripheral T-Cell Lymphomas (PTCL): Likelihood of Approval
CD30 is under clinical development by Wuhan Bio-Raid Biotechnology and currently in Phase I for Peripheral T-Cell Lymphomas (PTCL). According...
CD30 by Wuhan Bio-Raid Biotechnology for Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy: Likelihood of Approval
CD30 is under clinical development by Wuhan Bio-Raid Biotechnology and currently in Phase I for Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy....
CD30 by Wuhan Bio-Raid Biotechnology for T-Cell Leukemia: Likelihood of Approval
CD30 is under clinical development by Wuhan Bio-Raid Biotechnology and currently in Phase I for T-Cell Leukemia. According to GlobalData,...
CD30 by Wuhan Bio-Raid Biotechnology for T-Cell Lymphomas: Likelihood of Approval
CD30 is under clinical development by Wuhan Bio-Raid Biotechnology and currently in Phase I for T-Cell Lymphomas. According to GlobalData,...
CD30 by Wuhan Bio-Raid Biotechnology for Natural Killer Cell Lymphomas: Likelihood of Approval
CD30 is under clinical development by Wuhan Bio-Raid Biotechnology and currently in Phase I for Natural Killer Cell Lymphomas. According...